"İEÜ Medical Park Hastanesi, tüm branşların yanı sıra Onkoloji, Kemik İliği ve Organ Nakli ve Mikro-cerrahi alanlarında ön plana çıkıyor. Erişkin ve pediatrik kemik iliği, karaciğer, böbrek, pankreas, ince bağırsak, kalp, akciğer nakli gibi tüm organ nakli alanlarında Türkiye'de komple çözüm getiren bir organ nakli merkezi olmayı, nakil merkezimizle Dünyada organ nakli yapan hastaneler arasında referans olmayı, PET-CT ve LINAC cihazlarımızla Ege Bölgesi'nde onkoloji alanında da geniş bir hizmet yelpazesi sunmayı, Gamma-Knife teknolojisini Ege Bölgesi'ne getirmeyi amaçlıyor."

During the past decade, Izmir Medical Park Hospital conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 5 clinical trials were completed, i.e. on average, 20.8% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 5 clinical trials were completed. i.e. 35.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Izmir Medical Park Hospital" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Janssen Research & Development, LLC" with 6 trials sponsored, "Daiichi Sankyo, Inc." with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Celgene" with 2 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Izmir Medical Park Hospital" #1 collaborator was "AstraZeneca" with 2 trials as a collaborator, "NSABP Foundation Inc" with 2 trials as a collaborator, "Zai Lab (Shanghai) Co., Ltd." with 2 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "CenTrial GmbH" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Izmir Medical Park Hospital" are "Breast Cancer" (2 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Urinary Bladder Neoplasms" (2 trials), "Atrial Fibrillation and Flutter" (1 trials) and "Carcinoma, Transitional Cell" (1 trials). Many other conditions were trialed in "Izmir Medical Park Hospital" in a lesser frequency.

Most popular intervention types in "Izmir Medical Park Hospital" are "Drug" (19 trials), "Biological" (4 trials), "Other" (4 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (5 trials), "Carboplatin" (5 trials), "Placebo" (5 trials), "Cisplatin" (4 trials) and "Pemetrexed" (4 trials). Other intervention names were less common.

The vast majority of trials in "Izmir Medical Park Hospital" are 24 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Izmir Medical Park Hospital". undefined are not yet recruiting, 9 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Izmir Medical Park Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Izmir Medical Park Hospital, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".

Izmir Medical Park Hospital has several departments that took part in Clinical trials: "İzmir Medical Park; Onkoloji" - 5 trials